Search

Your search keyword '"Frieling, Helge"' showing total 1,066 results
Start Over Author "Frieling, Helge"
1,066 results on '"Frieling, Helge"'

3. Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients—a randomized rater-blinded trial

Author

Maier, Hannah Benedictine, Neyazi, Alexandra, Bundies, Gabriel L., Meyer-Bockenkamp, Fiona, Bleich, Stefan, Pathak, Hansi, Ziert, Yvonne, Neuhaus, Barbara, Müller, Franz-Josef, Pollmann, Iris, Illig, Thomas, Mücke, Stefanie, Müller, Meike, Möller, Brinja Kira, Oeltze-Jafra, Steffen, Kacprowski, Tim, Voges, Jan, Müntefering, Fabian, Scheiber, Josef, Reif, Andreas, Aichholzer, Mareike, Reif-Leonhard, Christine, Schmidt-Kassow, Maren, Hegerl, Ulrich, Reich, Hanna, Unterecker, Stefan, Weber, Heike, Deckert, Jürgen, Bössel-Debbert, Nicole, Grabe, Hans J., Lucht, Michael, and Frieling, Helge

Published
2024
Full Text
View/download PDF

10. Bifrontal electroconvulsive therapy leads to improvement of cerebral glucose hypometabolism in frontotemporal dementia with comorbid psychotic depression – a case report

Author

Schröder, Sebastian, Bönig, Lena, Proskynitopoulos, Phileas Johannes, Janke, Eva, Heck, Johannes, Mahmoudi, Nima, Groh, Adrian, Berding, Georg, Wedegärtner, Felix, Deest-Gaubatz, Stephanie, Maier, Hannah Benedictine, Bleich, Stefan, Frieling, Helge, and Schulze Westhoff, Martin

Published
2023
Full Text
View/download PDF

11. The significance of cerebrospinal fluid analysis in the differential diagnosis of 564 psychiatric patients: Multiple sclerosis is more common than autoimmune-encephalitis

Author

Maier, Hannah Benedictine, Stadler, Jan, Deest-Gaubatz, Stephanie, Borlak, Francesca, Türker, Seda Nur, Konen, Franz Felix, Seifert, Johanna, Kesen, Cagla, Frieling, Helge, Bleich, Stefan, Lüdecke, Daniel, Gallinat, Jürgen, Hansen, Niels, Wiltfang, Jens, Skripuletz, Thomas, and Neyazi, Alexandra

Published
2024
Full Text
View/download PDF

39. Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group.

Author

Maier, Hannah B., Borchert, Anton, Neyazi, Alexandra, Moschny, Nicole, Schülke, Rasmus, Bundies, Gabriel L., Folsche, Thorsten, Gaspert, Anastasia, Seifert, Johanna, Bleich, Stefan, Scherf-Clavel, Maike, Unterecker, Stefan, Deckert, Jürgen, Frieling, Helge, and Weber, Heike

Subjects
ELECTROCONVULSIVE therapy, CYTOCHROME P-450, PHENOTYPES, DRUG therapy, SOMATOFORM disorders, CONTROL groups
Abstract

Background Approximately 15–25% of depressed patients suffer from difficult-to-treat depression (DTD). Patients with DTD require a thorough examination to avoid the oversight of treatable (psychiatric/somatic) comorbidities or (pseudo-)resistance to antidepressant drugs (ADs). Polymorphisms of the cytochrome P450 (CYP) enzymes 2D6 and 2C19, which play a major role in the metabolism of ADs, may contribute to resistance to ADs. Patients with DTD might benefit from electroconvulsive therapy (ECT). Methods We enrolled 109 patients with DTD and 29 untreated depressed controls (UDC). We assessed risk phenotypes, comorbidities, and treatment, including ECT. We also performed pharmacokinetic analyses of CYP2D6 and CYP2C19. Results DTD patients significantly more often suffered from comorbid psychiatric diseases, especially ICD-10: F40-F48 (DTD:40.4%, UDC:17.2%, OR 11.87, p =0.011) than UDC patients. DTD patients receiving ECT were more likely to achieve remission (37.7% vs. 11.8%, OR=3.96, p =0.023). Treatment with ADs did not differ between remitters and non-remitters. No significant differences were observed in the distribution of CYP2D6 and CYP2C19 variants between both groups. Conclusion Patients with DTD appear to experience comorbid neurotic stress and somatoform disorders (ICD-10: F40 – F48) more frequently. Therefore, a comprehensive differential diagnosis is crucial when patients do not respond sufficiently to antidepressant medication. Genotyping CYP2D6 and CYP2C19 should be considered. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel

Author

Andrea Fagiolini, José Ángel Alcalá, Thomas Aubel, Wojciech Bienkiewicz, Mats Magnus Knut Bogren, Joaquim Gago, Giancarlo Cerveri, Michael Colla, Francisco Collazos Sanchez, Alessandro Cuomo, Frieling Helge, Eduardo Iacoponi, Per-Axel Karlsson, Pradeep Peddu, Mauro Pettorruso, Henrique Jorge Ramos Pereira, Johan Sahlsten Schölin, and Ingo Bernd Vernaleken

Subjects
Schizophrenia, Antipsychotics, Cariprazine, Patient subgroups, Recommendations, Negative symptoms, Psychiatry, RC435-571
Abstract

Abstract Background Management of schizophrenia is sub-optimal in many patients. Targeting negative symptoms, among the most debilitating aspects of schizophrenia, together with positive symptoms, can result in significant functional benefits and dramatically improve quality of life for patients and their carers. Cariprazine, a partial agonist of the dopamine receptors D2/D3 has demonstrated effectiveness across symptom domains in clinical trials, particularly on negative symptoms. Objective To obtain a broader insight from clinicians with specific experience with cariprazine, on how it affects patient populations outside the clinical trial setting. Methods The panel addressed a series of psychopharmacologic topics not comprehensively addressed by the evidence-based literature, including characteristics of patients treated, dosing and switching strategies, duration of therapy, role of concomitant medications and tolerability as well as recommendations on how to individualize cariprazine treatment for patients with schizophrenia. Results Patients recommended for cariprazine treatment are those with first episodes of psychosis, predominant negative symptoms (maintenance/acute phase) and significant side effects (metabolic side effects, hyperprolactinemia, sedation) with other antipsychotics. When the long-term treatment of a lifetime illness is adequately weighted, cariprazine becomes one of the first-line medications, not only for patients with predominant negative symptoms but also for those with relatively severe positive symptoms, especially if they are at the first episodes and if a specific medication is added for symptoms such as agitation or insomnia. For instance, patients with agitation may also benefit from the combination of cariprazine and a benzodiazepine or another sedating agent. Cariprazine may be prescribed as add-on to medications such as clozapine, when that medication alone is ineffective for negative symptoms, and sometimes the first may be discontinued or its dose lowered, after a period of stability, leaving the patient on a better tolerated antipsychotic regimen. Conclusions Based on real-world clinical experience, the panel considered that cariprazine, with its distinct advantages including pharmacokinetics/pharmacodynamics, good efficacy and tolerability, represents a drug of choice in the long-term management of schizophrenia not only for patients with predominant negative symptoms but also for those with positive symptoms.

Published
2020
Full Text
View/download PDF

50. Disparate effects of first and second generation antipsychotics on cognition in schizophrenia – Findings from the randomized NeSSy trial

Author

Bleich, Stefan, Borgmann, Markus, Breunig-Lyriti, Vasiliki, Schulz, Constanze, Brüne, Martin, Falkai, Peter, Feyerabend, Sandra, Figge, Christian, Frieling, Helge, Gaebel, Wolfgang, Gallinat, Jürgen, Handschuh, Dmitri, Heller, Jörg, Kirchhefer, Rainer, Kirner, André, Kowalenko, Barbara, Lautenschlager, Marion, Wolff-Menzler, Claus, Naber, Dieter, Prumbs, Katharina, Wobrock, Thomas, Veselinović, Tanja, Scharpenberg, Martin, Heinze, Martin, Cordes, Joachim, Mühlbauer, Bernd, Juckel, Georg, Habel, Ute, Rüther, Eckart, Timm, Jürgen, and Gründer, Gerhard

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results